Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid-implant designed to treat degenerative spinal pathologies in adults, including kyphosis.
The Jazz Claw seeks to provide autostable posterior fixation by replacing traditional hook-and-screw fixation systems.
The addition of Jazz Claw contributes to Implanet’s product portfolio for the treatment of degenerative spinal pathologies. Earlier this quarter, the company received regulatory approval for the Jazz Lock Implant.
Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid-implant designed to treat degenerative spinal pathologies in adults, including kyphosis.
The Jazz Claw seeks to provide autostable posterior fixation by replacing traditional hook-and-screw fixation systems.
Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid-implant designed to treat degenerative spinal pathologies in adults, including kyphosis.
The Jazz Claw seeks to provide autostable posterior fixation by replacing traditional hook-and-screw fixation systems.
The addition of Jazz Claw contributes to Implanet’s product portfolio for the treatment of degenerative spinal pathologies. Earlier this quarter, the company received regulatory approval for the Jazz Lock Implant.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
